Cagrilintide vs HGH Fragment 176-191

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Cagrilintide

Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.

Full details →

HGH Fragment 176-191

HGH Fragment 176-191 is the fat-reducing portion of the growth hormone molecule. Unlike AOD-9604 (which has an additional tyrosine), this is the exact fragment of HGH responsible for lipolytic effects.

Full details →

Side-by-Side Comparison

AspectCagrilintideHGH Fragment 176-191
MechanismActivates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1.Mimics the lipolytic region of growth hormone, stimulating fat breakdown and inhibiting lipogenesis without affecting blood sugar or promoting growth. Works independently of GH receptors.
Typical DosageClinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined.Typical dosing: 250-500mcg daily, often split into 2-3 doses. Usually administered on empty stomach, often with fasted cardio.
AdministrationSubcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved.Subcutaneous injection. Best results when used fasted and combined with exercise. Avoid eating for 30 minutes post-injection.
Side EffectsNausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially.Generally well-tolerated. May cause injection site irritation, temporary lethargy, or headache. Does not affect blood glucose significantly.
Best For

What They Have in Common

Both Cagrilintide and HGH Fragment 176-191 are commonly used for:

Ready to Learn More?